Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Acquired drug resistance in EGFR-mutant non-small-cell lung cancer (NSCLC) presents a significant therapeutic hurdle.
• Targeting resistant mutations like EGFR(L858R/T790M/C797S) is crucial for effective cancer treatment.

Purpose of the Study:

• To elucidate the molecular mechanisms behind the activity of novel trisubstituted imidazole inhibitors against resistant EGFR mutations.
• To provide insights for the development of next-generation EGFR inhibitors for NSCLC.

Main Methods:

• X-ray crystallography was employed to determine the binding modes of trisubstituted imidazole inhibitors with the EGFR kinase domain.
• Structure-activity relationship studies, including N-methylation, were performed to confirm key interactions.

Main Results:

• Trisubstituted imidazole inhibitors exhibit nanomolar potency against the triple mutant EGFR(L858R/T790M/C797S) via a reversible binding mechanism.
• The imidazole core acts as an H-bond acceptor for catalytic lysine 745 (K745) in the inactive 'αC-helix out' state.
• N-methylation of the imidazole nitrogen abolished inhibitor potency, confirming the critical role of this H-bond.

Conclusions:

• The K745 H-bond interaction is essential for potent, noncovalent inhibition of the C797S-resistant EGFR variant.
• These findings offer a structural basis for designing improved inhibitors targeting resistant EGFR mutations in NSCLC.